DeepMed Research

CINNAGEN

🇮🇷Iran

Country: 🇮🇷Iran

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients

Phase 3

Completed

Conditions: Mucopolysaccharidosis Type 1

Interventions: Biological: Laronidase
Drug: Antihistamine
Drug: Antipyretic

First Posted Date: 2024-05-09

Last Posted Date: 2024-08-06

Lead Sponsor: Cinnagen

Target Recruit Count: 12

Registration Number: NCT06406153

Locations: 🇮🇷
Loghman Hospital, Tehran, Iran, Islamic Republic of
🇮🇷
Clinical Research Development Unit of Akbar Hospital, Faculty of Medicine, Mashhad, Iran, Islamic Republic of
🇮🇷
Growth and Development Research Center, Childrens Medical Center, Tehran, Iran, Islamic Republic of

and more 1 locations

Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma

Phase 3

Completed

Conditions: Allergic Asthma
Uncontrolled Moderate to Severe

Interventions: Biological: Omalizumab (CinnaGen)
Biological: Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)

First Posted Date: 2023-04-14

Last Posted Date: 2023-04-14

Lead Sponsor: Cinnagen

Target Recruit Count: 256

Registration Number: NCT05813470

Locations: 🇮🇷
Golestan Hospital, Ahvaz, Iran, Islamic Republic of
🇮🇷
Imam Khomeini, Ahvaz, Iran, Islamic Republic of
🇮🇷
Dr.Tavakoul Office, Karaj, Iran, Islamic Republic of

and more 17 locations

Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration

Phase 3

Completed

Conditions: Age-Related Macular Degeneration
Neovascular Age-related Macular Degeneration

Interventions: Biological: Aflibercept (CinnaGen Co, Iran)
Biological: Aflibercept (Regeneron, USA)

First Posted Date: 2022-10-19

Last Posted Date: 2023-02-14

Lead Sponsor: Cinnagen

Target Recruit Count: 168

Registration Number: NCT05587062

Locations: 🇮🇷
Farabi Hospital, Tehran, Iran, Islamic Republic of

Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine

Not Applicable

Completed

Conditions: COVID-19

Interventions: Biological: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant

First Posted Date: 2022-03-17

Last Posted Date: 2023-08-31

Lead Sponsor: Cinnagen

Target Recruit Count: 43

Registration Number: NCT05285384

Locations: 🇮🇷
Shaheed Labbafinezhad Hospital, Tehran, Iran, Islamic Republic of

Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis

Phase 3

Completed

Conditions: Relapsing Remitting Multiple Sclerosis (RRMS)

Interventions: Drug: Pegylated interferon beta-1a
Drug: Interferon Beta-1A Prefilled Syringe

First Posted Date: 2022-02-16

Last Posted Date: 2022-10-18

Lead Sponsor: Cinnagen

Target Recruit Count: 168

Registration Number: NCT05242133

Locations: 🇮🇷
Sina Hospital, Tehran, Iran, Islamic Republic of

Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: Low-dose SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
Biological: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant

First Posted Date: 2022-02-09

Last Posted Date: 2022-10-17

Lead Sponsor: Cinnagen

Target Recruit Count: 581

Registration Number: NCT05231590

Locations: 🇮🇷
Orchid Life Department, Orchid Pharmed Company, Tehran, Iran, Islamic Republic of

Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine

Phase 3

Completed

Conditions: COVID-19

Interventions: Biological: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
Biological: Saline placebo

First Posted Date: 2022-01-04

Last Posted Date: 2022-10-14

Lead Sponsor: Cinnagen

Target Recruit Count: 300

Registration Number: NCT05175625

Locations: 🇮🇷
Orchid Life Department, Orchid Pharmed Company, Tehran, Iran, Islamic Republic of

Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

Phase 3

Completed

Conditions: Covid19

Interventions: Biological: Saline placebo
Biological: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant

First Posted Date: 2021-08-13

Last Posted Date: 2022-10-13

Lead Sponsor: Cinnagen

Target Recruit Count: 16876

Registration Number: NCT05005559

Locations: 🇮🇷
Espinas Palace Hotel, Tehran, Iran, Islamic Republic of

Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis

Phase 3

Completed

Conditions: Relapsing-Remitting
Multiple Sclerosis

Interventions: Biological: Ocrelizumab (CinnaGen, Iran)
Biological: Ocrelizumab (Roche, Switzerland)

First Posted Date: 2021-07-19

Last Posted Date: 2022-10-18

Lead Sponsor: Cinnagen

Target Recruit Count: 170

Registration Number: NCT04966338

Locations: 🇮🇷
Qaem International Hospital, Rasht, Guilan, Iran, Islamic Republic of
🇮🇷
Qaem Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of
🇮🇷
Sina Hospital, Hamadān, Iran, Islamic Republic of

and more 12 locations

Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer

Phase 3

Completed

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Pertuzumab
Drug: Carboplatin
Drug: Docetaxel

First Posted Date: 2021-07-12

Last Posted Date: 2024-07-26

Lead Sponsor: Cinnagen

Target Recruit Count: 214

Registration Number: NCT04957212

Locations: 🇮🇷
Qaem Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of
🇮🇷
Amir Hospital, Shiraz, Iran, Islamic Republic of
🇮🇷
Shahid Faghihi Hospital, Shiraz, Iran, Islamic Republic of

and more 41 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy